Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis

World Journal of Gastroenterology

Volumn 11, Issue 16, 2005, Pages 2462-2466

  Chen, Qi Kui ^a   Yuan, Shi Zheng ^a   Wen, Zhuo Fu ^a   Zhong, Ying Qiang ^a   Li, Cu Jun ^a   Wu, Hui Sheng ^b   Mai, Can Rong ^c   Xie, Peng Yan ^d   Lu, Yu Min ^d   Yu, Zhong Lin ^e  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d PEKING UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Pharmacodynamics; Sulfasalazine; Ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANOREXIA; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COLON POLYP; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTESTINE ULCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; RELAPSE; REMISSION; ULCERATIVE COLITIS; URTICARIA;

EID: 20844437078     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i16.2462     Document Type: Article

References (29)

1. Yang SK, Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001; 7: 260-270
2. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003; 15: 1275-1280
3. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149: 916-924
4. Probert CS, Jayanthi V, Rampton DS, Mayberry JF. Epidemiology of inflammatory bowel disease in different ethnic and religious groups: limitations and aetiological clues. Int J Colorectal Dis 1996; 11: 25-28
5. Sonnenberg A. Geographic variation in the incidence of and mortality from inflammatory bowel disease. Dis Colon Rectum 1986; 29: 854-861
6. Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am J Epidemiol 2001; 154: 328-335
7. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, Arca M, Berto E, Milite G, Marcheggiano A. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95: 1213-1220
8. National Symposium of Chronic and Non-infectious Intestinal Diseases. The criteria of diagnosis and treatment of inflammatory bowel disease. Zhonghua Xiaohua Zazhi 1993; 13: 354
9. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-976
10. Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts'dassification. Am J Gastroenterol 1995; 90: 1759-1763
11. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 5375: 89-92
12. Truelove SC, Richard WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 9: 1315-1318
13. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease(EC-IBD). Gut 1996; 39: 690-697
14. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17 (Suppl): S177-S185
15. Jiang ZL, Cui HF. Features of ulcerative colitis in China: an analysis 10218 cases. Shijie Huaren Xiaohua Zazhi 2001; 9: 869-873
16. Matsui T, Yao T, Sakurai T, Yao K, Hirai F, Matake H, Tsuda S, Wada Y, Iwashita A, Kamachi S. Clinical features and pattern of indeterminate colitis: Crohn's disease with ulcerative colitis-like clinical presentation. J Gastroenterol 2003; 38: 647-655
17. Farrokhyar F, Swarbrick ET, Grace RH, Hellier MD, Gent AE, Irvine EJ. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England. Am J Gastroenterol 2001; 96: 501-507
18. Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology 2004; 126: 665-673
19. Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004; 19: 529-535
20. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr 2004; 23: 161-170
21. Halme L, Turunen U, Helio T, Paavola P, Walle T, Miettinen A, Jarvinen H, Kontula K, Farkkila M. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol 2002; 37: 692-698
22. Moum B, Ekbom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histogical involvement in ulcerative colitis over time. Am J Gasteroenterol 1999; 94: 1564-1569
23. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD, Stevens AC. Clinical, biological, and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20
24. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540-549
25. Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs 2002; 62: 1689-1705
26. LaRosa D, Rubin PH, Bodian C, Present DH. Maintenance oral sulfasalazine prolongs remission in ulcerative proctitis and proctosigmoiditis. Am J Gastroenterol 1991; 86: 1456-1460
27. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003; 98(12 Suppl): S6-S17
28. Green JR, Swan CH, Gibson JA, Kerr GD, Swarbrick ET, Thornton PC. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. Aliment Pharmacol Ther 2004; 19: 435-442
29. Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004; 39: 154-157